Androgen-Insensitivity Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Background and Purpose- The safety of IV r-tPA (intravenous tissue-type plasminogen activator) for acute ischemic stroke (AIS) treatment after recent myocardial infarction (MI) is still a matter of debate.
|
31436141 |
2019 |
Androgen-Insensitivity Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Data from an international, multi-center, prospective, randomized, open-label, blinded-endpoint trial were used to assess the benefits and risks of low (0.6mg/kg) versus standard-dose (0.9mg/kg) intravenous alteplase in thrombolysis-eligible AIS patients.
|
29571842 |
2018 |
Androgen-Insensitivity Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our aim was to determine the best radiomics-based features of thrombus on NCCT and CT angiography associated with recanalization with IV alteplase in AIS patients and proximal intracranial thrombi.
|
30573458 |
2019 |
Androgen-Insensitivity Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine the extent to which the effects of intensive blood pressure (BP) lowering are modified by doses of alteplase in thrombolysis-eligible acute ischemic stroke (AIS) patients.
|
31812956 |
2019 |
Androgen-Insensitivity Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ENhanced Control of Hypertension And Thrombolysis strokE study (ENCHANTED) trial was initiated as a 2 × 2 partial-factorial active-comparison, prospective, randomized, open, blinded endpoint clinical trial to evaluate in thrombolysis-eligible acute ischemic stroke (AIS) patients whether: (1) Arm A - low-dose (0.6 mg/kg body weight) intravenous (iv) alteplase has noninferior efficacy and lower risk of symptomatic intracerebral hemorrhage (sICH) compared with standard-dose (0.9 mg/kg body weight) iv alteplase; and (2) Arm B - early intensive blood pressure (BP) lowering (systolic target 130-140 mmHg) has superior efficacy and lower risk of ICH compared with guideline-recommended BP control (systolic target <180 mmHg).
|
30299230 |
2019 |
Androgen-Insensitivity Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed a meta-analysis to compare the efficacy and safety between low- and standard-dose intravenous (IV) tissue-type plasminogen activator (tPA) for acute ischemic stroke (AIS) patients within 4.5 hours of symptom onset.
|
29224744 |
2018 |
Androgen-Insensitivity Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> We performed a pre-specified <i>post-hoc</i> subgroup analysis of the Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke (WAKE-UP) trial that randomized AIS patients with unknown time of symptom onset who had diffusion-weighted imaging-fluid attenuation inversion recovery (DWI-FLAIR) mismatch to either alteplase or placebo.
|
31824412 |
2019 |
Androgen-Insensitivity Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Accordingly, in the major group of thrombolyzed AIS patients who fail to reanalyze (>60%), t-PA might trigger unintended and potentially harmful immunosuppressive consequences instead of beneficial reperfusion.
|
30972077 |
2019 |
Androgen-Insensitivity Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Previous study demonstrates that lack of improvement (LOI) at 24 hours is an independent predictor of poor outcome and death at 3 months in patients with AIS treated with IV alteplase.
|
26971543 |
2017 |
Androgen-Insensitivity Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Retrospective analysis of prospectively collected single-center quality improvement data was performed of all acute ischemic stroke (AIS) patients treated with alteplase.
|
31836356 |
2020 |
Androgen-Insensitivity Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, after adjusting for confounders, AP was not associated with a higher risk of sICH and worse 3-month functional outcome in AIS treated with intravenous alteplase.
|
28550481 |
2017 |
Androgen-Insensitivity Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
All patients with AIS treated with intravenous alteplase between January 2005 and July 2016 were included.
|
30037650 |
2018 |
Androgen-Insensitivity Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The primary objective was to evaluate predictors of functional outcome in acute ischaemic stroke (AIS) patients treated with IV rt-PA.
|
30488077 |
2019 |
Androgen-Insensitivity Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In all, 3,284 thrombolysis-eligible AIS patients (mean age 66.6 years; 38% women), with information on lipid-lowering pretreatment, were randomly assigned to low-dose (0.6 mg/kg) or standard-dose (0.9 mg/kg) intravenous alteplase within 4.5 h of symptom onset.
|
29705803 |
2018 |